Accuitive Medical Ventures
VC Fund
Duluth, United States
Accuitive Medical Ventures (AMV) is a medical device venture capital firm. AMV is in business to finance and help develop early and expansion stage medical device and technology companies.
- Total investments:
- 27
- Last investment:
- Lead investor:
- 11%
Last updated:
For AI agents: llms.txt
Industries Accuitive Medical Ventures invests in
Stages Accuitive Medical Ventures invests in
Countries Accuitive Medical Ventures invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Charles E. Larsen
|
|||
Thomas D. Weldon
|
|||
Anthony Lando
|
|||
Gordon T. Wyatt
|
Investment Focus
Industry
- Medical Device 11 (41%)
- Health Care 10 (37%)
- Biotechnology 6 (22%)
- Medical 3 (11%)
- Therapeutics 3 (11%)
Stage
- Series D 8 (30%)
- Series C 6 (22%)
- Funding Round 4 (15%)
- Series E 3 (11%)
- Series G 2 (7%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Charles E. Larsen
Co-Founder & Managing Director
|
Co-Founder & Managing Director | Total investments: 4 | Find email | |
|
Thomas D. Weldon
Co-Founder, Chairman, and Managing Director
|
Co-Founder, Chairman, and Managing Director | Total investments: 4 | Find email | |
|
Anthony Lando
Partner
|
Partner | Total investments: 0 | Find email | |
Gerard van Hamel Platerink
Venture Partner & Co-Founder
|
Venture Partner & Co-Founder | Total investments: 2 | Find email | |
|
Gordon T. Wyatt
CFO
|
CFO | Total investments: 0 | Find email | |
| See all 6 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Intuity Medical
|
Intuity Medical develops blood glucose monitoring systems for diabetes management. Their POGO Automatic Blood Glucose Monitoring System is the world’s first FDA-cleared automatic, one-step blood glucose meter that combines lancing, blood collection, and analysis into a single 10-test cartridge. It provides a convenient and discreet solution formillions of patients who need to regularly test their blood glucose.The company was founded in 2002 and is headquartered in Fremont, California. | $70M / Jan 08, 2018 | |
Sebacia
|
Sebacia, Inc. is a private medical device company dedicated to creating breakthrough topical therapies for the treatment of dermatological conditions affecting millions of people. Sebacia's goal is to provide a better alternative to the daily use of topical and systemic drugs currently available for the treatment of acne. Sebacia'spatented microparticles technology was invented at Rice University, and the proprietary dermatology applications were further developed with researchers from the Wellman Center of Photomedicine at Massachusetts General Hospital. Sebacia is located in Duluth, Georgia. | $20M / Series D / Jul 25, 2017 | |
Neuronetics
|
Neuronetics is focused on developing non-invasive therapies for psychiatric and neurological disorders using MRI-strength magnetic field pulses. They are the first and only company to have a non-systemic and non-invasive depression treatment cleared by the FDA for patients who have not benefited from prior antidepressant treatment. | $15M / Series G / Jun 06, 2017 | |
Torax Medical
|
Torax Medical, Inc., a clinical stage medical device company, develops an implantable device for the treatment of gastroesophageal reflux disease. It provides treatments for digestive diseases, including acid reflux. The company was founded in 2002 and is based in Shoreview, Minnesota. | $25M / Series E / Jul 26, 2016 | |
|
Sebacia
|
Sebacia, Inc. is a private medical device company dedicated to creating breakthrough topical therapies for the treatment of dermatological conditions affecting millions of people. Sebacia's goal is to provide a better alternative to the daily use of topical and systemic drugs currently available for the treatment of acne. Sebacia'spatented microparticles technology was invented at Rice University, and the proprietary dermatology applications were further developed with researchers from the Wellman Center of Photomedicine at Massachusetts General Hospital. Sebacia is located in Duluth, Georgia. | $12M / Series C / Jun 25, 2015 | |
AcuFocus
|
Acufocus, Inc., a medical device company, engages in the research, development, and marketing of solutions for the treatment of presbyopia. The company develops KAMRA, a corner inlay for the treatment of near vision loss that allows patients to see near and intermediate objects clearly; and AcuTarget, a system that is used to guide surgeons onsurgical placement of the KAMRA.It was founded in 2011 and headquartered in Irvine, California. | $21M / Sep 03, 2014 | |
|
AcuFocus
|
Acufocus, Inc., a medical device company, engages in the research, development, and marketing of solutions for the treatment of presbyopia. The company develops KAMRA, a corner inlay for the treatment of near vision loss that allows patients to see near and intermediate objects clearly; and AcuTarget, a system that is used to guide surgeons onsurgical placement of the KAMRA.It was founded in 2011 and headquartered in Irvine, California. | $21M / Series G / Sep 03, 2014 | |
AqueSys
|
The Innovation Factory acquires novel medical technology ideas from individual inventors, corporations and universities, develops ideas comprehensively from proof of concept to FDA approval into marketable products, and then launches businesses around those products. We manage the complex path to market for early-stage medical device companies.With our deeply experienced management team and top-tier funding partners, we have assembled the intellectual, scientific, operational and financial resources needed to take a great idea from paper to production. Our nimble approach to both product and business development allows us to vet ideas properly and efficiently, maximizing predictability and speeding time-to-market while reducing risk for everyone involved.The Innovation Factory welcomes medical-related ideas and referrals from a variety of sources, and we promise confidentiality and timely response to all inquiries. For more information, please select the appropriate perspective: Inventor, University or Corporation. | $43.6M / Series D / Jan 16, 2014 | |
MyoScience
|
MyoScience Inc. engages in development and commercialization of technology driven dermatological products. MyoScience Inc. was founded in 2005 and is headquartered in Redwood City, California. | $25M / Series E / Sep 12, 2013 | |
|
Torax Medical
|
Torax Medical, Inc., a clinical stage medical device company, develops an implantable device for the treatment of gastroesophageal reflux disease. It provides treatments for digestive diseases, including acid reflux. The company was founded in 2002 and is based in Shoreview, Minnesota. | $30M / Series D / Sep 19, 2012 | |
| See all 27 investments → | |||
Co-Investors
Versant Ventures
19 deals together
SV Health Investors
11 deals together
The Carlyle Group
10 deals together
Essex Woodlands Healthcare Partners
5 deals together
Bausch & Lomb
4 deals together
Investor Growth Capital Limited
4 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Accuitive Medical Ventures invest in?
Accuitive Medical Ventures invests primarily in Medical Device, Health Care and Biotechnology startups, most often at Series D and Series C stage. Most of the 27 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Accuitive Medical Ventures?
Public channels for Accuitive Medical Ventures include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Accuitive Medical Ventures?
The team at Accuitive Medical Ventures includes Charles E. Larsen (Co-Founder & Managing Director), Thomas D. Weldon (Co-Founder, Chairman, and Managing Director) and Anthony Lando (Partner), among 6 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
